Thomson Reuters IP & Science 2015
Thompson Reuters

Blog

22 May 2015

World’s largest asset manager enters the IP financing game with wearables patent loan

BlackRock – the world’s biggest investment firm with over $4.6 trillion of assets under management – is loaning wearable technology company Jawbone $300 million against its intellectual property and other intangible assets. According to a Bloomberg report - quoting regulatory filings in California and people involved in the deal - the loan from BlackRock is secured by Jawbone's “current and future licences, intellectual property, royalties, accounts receivable and Read more

Jack Ellis

21 May 2015

PWC’s annual litigation report shows just how stacked the US patent system is against the small inventor

If you’re a regular patent market observer there’s probably not too much to surprise you in PWC’s latest patent litigation report. Covering 2014, it shows that the overall number of cases in the year was down, but that was already apparent from studies previously put out by the likes of Lex Machina, RPX and Unified Patents. That said, there is a discrepancy in the numbers that have been reported, but that’s because PWC’s cover the 12 months to 30th September 2014 Read more

Richard Lloyd

21 May 2015

Don’t call it a tie-up, but Xiaomi is inching toward patent self-sufficiency with Leadcore link

The rollout of Xiaomi’s Redmi 2A last month may have marked the beginning of a new era for the company. The low-cost smartphone was the first to feature a chipset from Chinese fabless chipmaker Leadcore rather than usual vendors Qualcomm and Mediatek. The much-speculated upon partnership illustrates the convergence of interests between a central government keen to encourage home-grown technology and Chinese companies seeking greater IP protection. This blog first covered the linkup Read more

Jacob Schindler

19 May 2015

There is nothing wrong with privateering; patent owners are entitled to maximise the value of their assets

In the last couple of years there have been several attempts to stymie privateering – the model by which operating companies sell patents to an NPE which then seeks to monetise them, usually through an assertion campaign. The original owner may retain some financial interest in the ongoing programme, but typically doesn’t have any control over how they are asserted. Google, for one, has staked out its clear opposition to what it sees as a major source of patents for Read more

Richard Lloyd

19 May 2015

It's not all doom and gloom for pharmaceutical innovators in India

Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet (though it can keep selling its existing inventory). The decision follows a flap over the release of the United States Trade Representative’s Special 301 Report , which prompted pushback with its criticism of pharmaceutical patent protection Read more

Jacob Schindler

18 May 2015

The USPTO has the power to create a much more equitable IPR process; and it should do so

Since the America Invents Act overhauled the re-examination process, we have written regularly about the impact that the new procedures, and inter partes reviews in particular, have had on the patent market. Essentially, they have become a new tool with which to challenge patent validity and have helped shift the prevailing dynamic from one of whether a patent has been infringed to whether some or all of an issued patent’s claims should have been allowed. While they have proved very Read more

Richard Lloyd

17 May 2015

The PPP may be great news for Google, but less good for the blood pressures of its patent team members

Ten days in and Google’s Patent Purchase Promotion (PPP) is already attracting a great deal of interest, according to the latest reports. Last week at the Spring meeting of LES USA and Canada, Black Stone IP Director Matt Moyers tweeted that Google's head of patent acquisitions Kirk Dailey had stated in  a panel discussion at the event that the PPP “has had significant traction” since it got underway on 8th May, with prices set ranging from $1 to $2.3 billion and Read more

Joff Wild

15 May 2015

WIPO assembly chair calls in central UN unit to investigate the explosive claims against DG Francis Gurry

Päivi Kairamo, chair of WIPO’s General Assemblies, has asked the United Nations’ Organisation of Internal Oversight Services (OIOS) to investigate the claims made by James Pooley, the former deputy director general of the organisation, in a Report of Misconduct he filed last April in which he made a series of explosive allegations against current Director General Francis Gurry. This development was first reported on the Fox News website on Wednesday and has now been Read more

Joff Wild

15 May 2015

Compulsory licensing is not just a risk factor in India and other emerging markets

The following is a brief extract from a letter which a national legislator sent to a member of the cabinet earlier this week: “I ask you to utilise federal law… to break the patents on these drugs to authorise third parties to manufacture or import them for government use.” The drug in question here is the hepatitis-C treatment sofosbuvir, which is marketed under the brand name Sovaldi by Gilead Sciences, the company that owns the patent on it. This blog has previously Read more

Jack Ellis

14 May 2015

Monetisation options outside the courtroom are growing, but their ability to deliver remains open to question

If you’re a patent owner, monetising your IP in the US may seem like a tough task right now. The traditional licensing route has become so mired in litigation and re-exam challenges that it is increasingly only open to the richest plaintiffs. And although we recently reported on an uptick in sales in the first three months of this year, it is widely acknowledged that patent values are depressed. In short, it is not a sellers market. But that doesn’t mean owners don’t have Read more

Richard Lloyd

Close

Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 0